SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 139 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,106,659 | -33.1% | 2,555,555 | -3.6% | 0.58% | -23.0% |
| Q2 2023 | $55,464,500 | -0.9% | 2,650,000 | 0.0% | 0.75% | -9.4% |
| Q1 2023 | $55,968,000 | -17.0% | 2,650,000 | 0.0% | 0.83% | -17.7% |
| Q4 2022 | $67,442,500 | +26.3% | 2,650,000 | +19.3% | 1.01% | +2.1% |
| Q3 2022 | $53,400,000 | +24.9% | 2,222,222 | 0.0% | 0.99% | +16.8% |
| Q2 2022 | $42,756,000 | +10.8% | 2,222,222 | +0.1% | 0.84% | +19.9% |
| Q1 2022 | $38,592,000 | -18.9% | 2,220,500 | +2.1% | 0.70% | -13.0% |
| Q4 2021 | $47,611,000 | +61.3% | 2,175,000 | +40.8% | 0.81% | +74.6% |
| Q3 2021 | $29,525,000 | -42.7% | 1,545,000 | -48.5% | 0.46% | -48.2% |
| Q2 2021 | $51,510,000 | -7.9% | 3,000,000 | +20.0% | 0.90% | -7.2% |
| Q1 2021 | $55,900,000 | +458.6% | 2,500,000 | +455.6% | 0.96% | +461.0% |
| Q4 2020 | $10,008,000 | – | 450,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |